On March 23, BioClin Therapeutics announced the completion of a $30 million Series B round of financing. This round of investment was led by new investors Sofinnova Ventures and Ysios Capital, as well as existing investors HealthCap, Life Sciences Partners (LSP) and Tekla Capital Management. Since the company's inception, BioClin has raised a total of $59 million. BioClin Therapeutics is a clinical stage drug company. The company's leading drug candidate is B-701, a potential first-in-class human monoclonal antibody that targets FGFR3 (fibroblast growth factor receptor 3). Currently, the company is evaluating the efficacy of B-701 in the treatment of metastatic bladder cancer. The proceeds from this round of financing will be used to promote the clinical development of the company's B-701, especially for the treatment of patients with metastatic bladder cancer or metastatic urothelial carcinoma (mUC), who are relapsed or refractory to platinum drugs. Sex. BioClin's products are in the research line (Source: BioClin's official website) Stephen Lau, CEO of BioClin Therapeutics, said: "This financing enabled us to expand our 1b/2 trial using B-701 in combination with docetaxel and initiated an assessment of B-701 in combination with atezolizumab Phase 1b/2 trial of anti-drug." Phase 1b/2 study of B-701 in combination with docetaxel will recruit a cohort of patients with FGFR3 mutation or fusion; patients will be given B-701 plus docetaxel or B-701 alone Monotherapy. The second study will evaluate the combination of B-701 and atezolizumab in patients with mUC, including patients overexpressing FGFR3 and FGFR3 mutations or fusion tumors. Antioxidants Vitamins,Antioxidant Vitamins Tablets,Rubber Antioxygen,Antioxidants Free Radicals SHANDONG BAISHENG BIOTECHNOLOGY CO., LTD , https://www.baishengbioproducts.com
Targeted treatment of bladder cancer: BioClin received $30 million in Series B financing